Literature DB >> 19263139

Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus: initial results and lessons learned.

Vic Velanovich1.   

Abstract

BACKGROUND: Ablating Barrett's epithelium may reduce the risk of developing esophageal adenocarcinoma. This study reports the experience of a single surgeon using an endoscopic endoluminal device that delivers radiofrequency energy (the BARRx device) to ablate Barrett's esophagus.
METHODS: All patients who underwent ablation of Barrett's epithelium with the BARRx system were reviewed for length of Barrett's metaplasia, presence of high-grade dysplasia, postprocedure complications, completeness of ablation at first follow-up endoscopy, need for additional ablation, completeness of ablation at second follow-up endoscopy, and concomitant performance of a Nissen fundoplication.
RESULTS: Sixty-six patients underwent Barrett's ablation. The median length of the Barrett's esophagus was 3 (range, 1-14) cm. Twelve patients (18%) had high-grade dysplasia. There were no immediate procedure-related complications. Four strictures occurred: three in patients with > or = 12-cm segments of Barrett's and one in a 6-cm segment. Twenty-nine of 49 patients (59%) who had planned 3-month follow-up endoscopy had complete ablation. Five patients had planned two-stage ablation. Twenty patients with incomplete ablation had additional ablation. Twenty-seven patients had planned follow-up endoscopy at > or = 1 year: 25 of 27 (93%) had biopsy-proven normal esophageal mucosa. The median length of Barrett's esophagus in patients with initially incomplete ablation was 6 cm, compared with 2 cm in the initially complete ablation patients. Seven Nissen fundoplications were present at the time of ablation, whereas six were performed concomitantly with the ablation without increased difficulty.
CONCLUSIONS: Complete ablation of Barrett's esophagus with radiofrequency endoluminal ablation is achievable in > 90% of patients. Patients with longer segments are likely to require additional ablation. Patients with very long segments are at risk for stricture and should be approach cautiously. Performance of a fundoplication is not hindered by concomitant ablation.

Entities:  

Mesh:

Year:  2009        PMID: 19263139     DOI: 10.1007/s00464-009-0364-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  31 in total

1.  Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus.

Authors:  Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

Review 2.  A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop.

Authors:  Prateek Sharma; Kenneth McQuaid; John Dent; M Brian Fennerty; Richard Sampliner; Stuart Spechler; Alan Cameron; Douglas Corley; Gary Falk; John Goldblum; John Hunter; Janusz Jankowski; Lars Lundell; Brian Reid; Nicholas J Shaheen; Amnon Sonnenberg; Kenneth Wang; Wilfred Weinstein
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

3.  Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness.

Authors:  Krish Ragunath; Neville Krasner; V Sankara Raman; Mustafa T Haqqani; Ceri J Phillips; Ivy Cheung
Journal:  Scand J Gastroenterol       Date:  2005-07       Impact factor: 2.423

4.  Can deep freezing join the endoscopic Barrett's mucosal ablation party? Cautious optimism is warranted.

Authors:  Allan P Weston
Journal:  Gastrointest Endosc       Date:  2005-12       Impact factor: 9.427

5.  Thermal ablation of Barrett's esophagus: a heated debate.

Authors:  Stuart J Spechler
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

6.  Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia.

Authors:  A K Roorda; S N Marcus; G Triadafilopoulos
Journal:  Dis Esophagus       Date:  2007       Impact factor: 3.429

7.  Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.

Authors:  Bergein F Overholt; Charles J Lightdale; Kenneth K Wang; Marcia I Canto; Steven Burdick; Roger C Haggitt; Mary P Bronner; Shari L Taylor; Michael G A Grace; Michelle Depot
Journal:  Gastrointest Endosc       Date:  2005-10       Impact factor: 9.427

8.  Improving surveillance for Barrett's oesophagus.

Authors:  Peter A Bampton; Anne Schloithe; Jeff Bull; Robert J Fraser; Rob T A Padbury; David I Watson
Journal:  BMJ       Date:  2006-06-03

9.  Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data.

Authors:  J David Horwhat; Darren Baroni; Corinne Maydonovitch; Eric Osgard; Eric Ormseth; Eugenia Rueda-Pedraza; Hyun J Lee; William K Hirota; Roy K H Wong
Journal:  Am J Gastroenterol       Date:  2007-03       Impact factor: 10.864

10.  Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system.

Authors:  C D Smith; P A Bejarano; W S Melvin; M G Patti; R Muthusamy; B J Dunkin
Journal:  Surg Endosc       Date:  2006-12-16       Impact factor: 3.453

View more
  14 in total

1.  The cost effectiveness of radiofrequency ablation for Barrett's esophagus.

Authors:  Chin Hur; Sung Eun Choi; Joel H Rubenstein; Chung Yin Kong; Norman S Nishioka; Dawn T Provenzale; John M Inadomi
Journal:  Gastroenterology       Date:  2012-05-21       Impact factor: 22.682

Review 2.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

3.  Endoscopic resection techniques and ablative therapies for Barrett's neoplasia.

Authors:  Jacobo Ortiz-Fernández-Sordo; Adolfo Parra-Blanco; Alejandro García-Varona; María Rodríguez-Peláez; Erika Madrigal-Hoyos; Irving Waxman; Luis Rodrigo
Journal:  World J Gastrointest Endosc       Date:  2011-09-16

4.  Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus.

Authors:  Jacques J G H M Bergman; Yue-Ming Zhang; Shun He; Bas Weusten; Liyan Xue; David E Fleischer; Ning Lu; Sanford M Dawsey; Gui-Qi Wang
Journal:  Gastrointest Endosc       Date:  2011-08-15       Impact factor: 9.427

5.  Barrett's esophagus: endoscopic treatments II.

Authors:  Bruce D Greenwald; Charles J Lightdale; Julian A Abrams; John D Horwhat; Ram Chuttani; Srinadh Komanduri; Melissa P Upton; Henry D Appelman; Helen M Shields; Nicholas J Shaheen; Stephen J Sontag
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

6.  Diagnosis and management of Barrett's esophagus for the endoscopist.

Authors:  Sagar S Garud; Steven Keilin; Qiang Cai; Field F Willingham
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

7.  Endoscopic management of early esophageal neoplasia: an emerging standard.

Authors:  Kelly M Galey; Candice L Wilshire; Thomas J Watson; Marabel D Schneider; Vivek Kaul; Carolyn E Jones; Virginia R Litle; Asad Ullah; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2011-08-03       Impact factor: 3.452

Review 8.  Ablative therapies for Barrett's esophagus.

Authors:  Katherine S Garman; Nicholas J Shaheen
Journal:  Curr Gastroenterol Rep       Date:  2011-06

9.  Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett's esophagus.

Authors:  Kathleen O'Connell; Vic Velanovich
Journal:  Surg Endosc       Date:  2010-07-30       Impact factor: 4.584

10.  Treatment of ultralong-segment Barrett's using focal and balloon-based radiofrequency ablation.

Authors:  Melina C Vassiliou; Daniel von Renteln; Daniel C Wiener; Stuart R Gordon; Richard I Rothstein
Journal:  Surg Endosc       Date:  2009-08-27       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.